Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-20T07:37:15.407Z Has data issue: false hasContentIssue false
  • English
  • Français

Empiric Antimicrobial Therapy in the Febrile Granulocytopenic Patient

Published online by Cambridge University Press:  05 January 2022

Michael Scheld  and
Walter T. Hughes
Michael Scheld
Affiliation:
Department of Infectious Diseases, St. Jude Children's Research' Hospital, Memphis, Tennessee
Walter T. Hughes*
Affiliation:
Department of Infectious Diseases, St. Jude Children's Research' Hospital, Memphis, Tennessee
*
St. Jude Children's Research Hospital, 332 N. Lauderdale, Memphis, TN 38101
Get access Rights & Permissions [Opens in a new window]

Extract

In the normal individual, about 100 billion polymorphonuclear leukocytes (neutrophils) enter the bloodstream daily from the bone marrow. About half of the intravascular neutrophils are adherent (marginated) to the endothelium of small vessels and the remainder are circulating. Without unusual disturbances, the half-life of the intravascular neutrophil is about six hours. Although the number of circulating neutrophils seems enormous, it represents only 5% of the total body content of these cells, the major portion residing in the bone marrow.

It is remarkable that quantitation ofpolymorphonuclear leukocytes in a drop of peripheral blood can be highly predictive of an individual's resistance and response to infectious diseases, especially those caused by bacteria. Neutrophil activity is complex and its role in host defense is dependent upon factors other than quantity. Nevertheless, when the absolute neutrophil count is maintained at values less than 1000/cu mm, increased susceptibility to infection occurs and is at a rate that is inversely proportional to the neutrophil count. When the count is decreased to values of 500 neutrophils/cu mm or less, the frequency of serious bacterial infection reaches a point where special attention must be directed to the patient at the earliest sign of infection.

Type
Special Sections
Information
Infection Control & Hospital Epidemiology , Volume 11 , Issue 3 , March 1990 , pp. 151 - 156
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1990

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Wade, BA, Mandell, GL. Polymorphonuclear leukocytes: dedicated professional phagocytes. Am J Med. 1983;74:686–693.CrossRefGoogle ScholarPubMed
2. EORTC International Antimicrobial Therapy Project Group. Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. J Infect Dis. 1978;137:14–29.CrossRefGoogle Scholar
3. The International Antimicrobial Therapy Project Group of the European Organization for Research and Treatment of Cancer. Combination of amikacin and carbenicillin with or without cefazolin as empirical treatment of febrile neutropenic patients. J Clan Oncol.1983;1:597–603.CrossRefGoogle Scholar
4. Cohen, ML, Murphy, MT. Counts, GW, et al. Prediction by surveillance cultures of bacteremia among neutropenic patients treated in a protective environment. J Infect Dis. 1983;147:789–793.CrossRefGoogle Scholar
5. Prince, A, Heller, B, Levy, J, Heird, WC. Management of fever in patients with central vein catheter. Pediatr Infect Dis J. 1986;5:20–24.CrossRefGoogle Scholar
6. Benezra, D, Kiehn, TE, Gold, JWM, et al. Prospective study of infections in indwelling central venous catheters using quantitative blood cultures. Am J Med. 1988;85:495–498.CrossRefGoogle ScholarPubMed
7. Flynn, PM. Shenep, JL, Stokes, DC, et al. In situ management of confirmed central venous catheter-related bacteremia. Pediatr Infect Dis J. 1987;6:729–734.CrossRefGoogle ScholarPubMed
8. Viscoli, C, Garaventa, A, Boni, L, et al. Role of Broviac catheters in infections in children with cancer. Pediatr Infect Dis J. 1988;7:556–560.Google ScholarPubMed
9. Pizza, PA, Ladisch, SL, Robichaud, KJ. Treatment of gram-positive septicemia in cancer patients. Cancer. 1980;45:206–207.3.0.CO;2-P>CrossRefGoogle Scholar
10. Infectious Diseases Society Of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever: a statement by the Infectious Diseases Society of America. J Infect Dis. In press.Google Scholar
11. Shenep, J. Hughes, WT, Roberson, PK, et al. Vancomycin, ticarcillin and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. N Engl J Med. 1988;319:1053–1058.CrossRefGoogle ScholarPubMed
12. Casali, A, Ameglio, F, Gionfra, T, et al. Amikacin plus ceftazidime versus amikacin plus pipercillin versus amikacin plus aztreonam in infections in neoplastic patients with granulocytopenia. Chemotherapia. 1987;6:440–444.Google ScholarPubMed
13. Piccart, M, Klastersky, J, Meunier, F, et al. Single-drug versus combination empirical therapy for gram-negative bacillary infection in febrile cancer patients with and without granulocytopenia. Antimicrob Agents Chemother. 1984;26:870–875.CrossRefGoogle ScholarPubMed
14. EORTC Antimicrobial Therapy Cooperative Groups. Ceftazidime plus amikacin with or without vancomycin as empirical therapy of fever in cancer patients with granulocytopenia. Abstract No. 18. Interscience Conf Antimicrob Agents Chemother. 1984;26:870–875.Google Scholar
15. Gucalp, R, Lisa, S, McKitrick, JC, et al. Cefoperazone plus tobramycin venous ticarcillin plus tobramycin in febrile granulocytopenic cancer patients. Am J Med. 1988;85(suppl 1A):31–35.CrossRefGoogle Scholar
16. Williams, ME, Harman, C, Scheld, M, et al. A controlled study of ticarcillin plus clavulamic acid versus piperacillin as empiric therapy for fever in the immunosuppressed host. Am J Med. 1985;79(suppl. 5B):67–72.CrossRefGoogle Scholar
17. DeJough, CA, Joshi, JH, Thompson, SW, et al. A double β-lactam combination versus an aminoglycoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients. Am J Med. 1986;80:101–111.Google Scholar
18. Winston, DJ, Winston, GH, Bruckner, DA, et al. Controlled trials of double β-lactam therapy with cefoperazone plus piperacillin in febrile granulocytopenic patients. Am J Med. 1988;85(suppl. 1A):21–30.CrossRefGoogle ScholarPubMed
19. Mortimer, J, Miller, S, Black, E, et al. Comparison of cefoperazones and mezlocillin with imipenem as empiric therapy in febrile neutropenic cancer patients. Am J Med. 1988;85(suppl 1A):17–20.CrossRefGoogle ScholarPubMed
20. Anaissie, EJ, Fainstein, V, Bodey, GP. Randomized trial of β-lactam regimen in febrile neutropenic cancer patients. Am J Med. 1988;44:581–589.CrossRefGoogle Scholar
21. Rotstein, C, Cimino, M, Winkey, K, et al. Cefoperazone plus piperacillin versus mezlocillin plus tobramcyin as empiric therapy for febrile episodes in neutropenic patients. Am J Med. 1988;85(suppl. 1A):36–39.CrossRefGoogle Scholar
22. EORTC International Antimicrobial Therapy Cooperative Group. Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. J Infect Dis. 1978;137:14–29.CrossRefGoogle Scholar
23. Pizza, PA, Hathorn, JW, Hiemenz, J, et al. A randomized trial comparing ceftazidime along with combination antibiotic therapy in cancer patients with fever and neutropenia. N Enggl J Med. 1986;315:552–558.CrossRefGoogle Scholar
24. Verhagen, CS, de Pauw, B, Dewitte, T, et al. Randomized prospective study of ceftazidime versus ceftazidine plus cephalothin in empiric treatment of febrile episodes in severely neutropenic patients. Antimicrob Agents Chemother. 1987;31:191–196.CrossRefGoogle Scholar
25. Wade, JC, Johnson, DE, Bustamante, CI. Monotherapy for empiric treatment of fever in granulocytopenic cancer patients. Am J Med. 1986;80(suppl. 5C):85–95.Google ScholarPubMed
26. Neu, HC. New oral and parenteral quimolones. Am J Med. 1989;87(Suppl. 5A):283–287(S).CrossRefGoogle Scholar
27. Granowetter, L, Wells, H, Lange, BJ. Ceftazidime with or without vancomycin vs cephalothin, carbenicillin and gentamicin as initial therapy of the febrile neutropenic pediatric cancer patient. Pediatr Infect Dis J. 1988;7:165–170.CrossRefGoogle ScholarPubMed
28. Karp, JE, Hick, JD, Angelopulos, C, et al. Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Am J Med. 1986;81:237–242.CrossRefGoogle ScholarPubMed
29. Kramer, BS, Ramphal, R, Rand, KH. Randomized comparison between two ceftazidime containing regimens and cephalothin-gentamicin-carbenicillin in febrile granulocytopenic cancer patients. Antimicrob Agents Chemother. 1986;30:64–68.CrossRefGoogle ScholarPubMed
30. Pizza, PA, Robichand, KJ, Gill, FA. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med. 1982;72:101–111.CrossRefGoogle Scholar
31. Stein, RS, Kayser, J, Flexner, J: Clinical value of empirical emphotericin B in patients with acute myelogenous leukemia. Cancer. 1982;50:2247–2251.3.0.CO;2-7>CrossRefGoogle ScholarPubMed
32. EORTC Antimicrobial Cooperative Group. Empiric therapy with fungizone in febrile neutropenic patients. Proceedings of the 26th Meeting Interscience Conf Antimicrob Agents Chemother. New Orleans, La. Abstract No. 683; 1986 Google Scholar
33. EORTC International Antimicrobial Therapy Cooperative Groups. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. New Engl J Med. 1987;317:1692–1698.CrossRefGoogle Scholar
34. O'Hanley, P, Easaw, J, Rugo, H, Easaw, S. Infectious disease management of adult leukemic patients undergoing chemotherapy: 1982 to 1986 experience at Stanford University Hospital. Am J Med. 1989;87:605–613.CrossRefGoogle ScholarPubMed